Arcutis Biotherapeutics (ARQT) Research & Development (2019 - 2026)

Arcutis Biotherapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 74.58% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $90.1 million (up 27.27% YoY), while the FY2025 annual figure was $77.1 million, up 0.83% from the prior year.
• Research & Development for Q1 2026 stood at $30.6 million, up from $20.5 million in the prior quarter.
• The five-year high for Research & Development was $40.6 million in Q1 2022, with the low at $14.5 million in Q4 2024.
• The 5-year median for Research & Development is $23.8 million (2023), against an average of $25.7 million.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 87.8% in 2022, then plunged 39.1% in 2024.
• Arcutis Biotherapeutics' Research & Development stood at $33.9 million in 2022, then fell by 29.82% to $23.8 million in 2023, then slumped by 39.1% to $14.5 million in 2024, then surged by 41.24% to $20.5 million in 2025, then jumped by 49.76% to $30.6 million in 2026.
• Business Quant data shows ARQT's Research & Development at $30.6 million in Q1 2026, $20.5 million in Q4 2025, and $19.6 million in Q3 2025.